Toposar50 mg
Capsule
Etoposide
Drug International Ltd.
Product Code : 17122
10% Off
Best PriceTk
/
1
Medicine overview
Indications of Toposar 50 mg
Small Cell Lung Cancer: Toposar 50 mg Capsules in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer.Toposar 50 mg is also indicated in Testicular cancer, Small cell lung cancer
Theropeutic Class
Cytotoxic Chemotherapy
Pharmacology
Toposar 50 mg is a derivative of podophyllotoxin that inhibits DNA synthesis resulting in the arrest of the cell cycle. At low doses, it inhibits cells from entering cell cycle and at high doses, cells entering mitosis are lysed.
Dosage & Administration of Toposar 50 mg
Intravenous (Adult)-
Small cell lung cancer: 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days. May repeat course at 3-4 wkly intervals after recovery from any toxicity. Inj must be diluted with 5% dextrose or normal saline to give a final concentration of 0.2-0.4 mg/ml and injected over 30-60 minutes. When given via oral capsules: the recommended dose is twice the IV dose rounded to the nearest 50 mg.Testicular cancer: For combination therapy: 50-100 mg/m2/day from days 1-5, or 100 mg/m2 on days 1, 3 and 5. May repeat course at 3-4 wkly intervals after recovery from any toxicity. Inj must be diluted with 5% dextrose or normal saline to give a final concentration of 0.2-0.4 mg/ml and injected over 30-60 minutes.
Oral (Adult)-
Small cell lung cancer: Twice the IV dose, rounded to the nearest 50 mg.
Dosage of Toposar 50 mg
Intravenous (Adult)-
Small cell lung cancer: 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days. May repeat course at 3-4 wkly intervals after recovery from any toxicity. Inj must be diluted with 5% dextrose or normal saline to give a final concentration of 0.2-0.4 mg/ml and injected over 30-60 minutes. When given via oral capsules: the recommended dose is twice the IV dose rounded to the nearest 50 mg.Testicular cancer: For combination therapy: 50-100 mg/m2/day from days 1-5, or 100 mg/m2 on days 1, 3 and 5. May repeat course at 3-4 wkly intervals after recovery from any toxicity. Inj must be diluted with 5% dextrose or normal saline to give a final concentration of 0.2-0.4 mg/ml and injected over 30-60 minutes.
Oral (Adult)-
Small cell lung cancer: Twice the IV dose, rounded to the nearest 50 mg.
Interaction of Toposar 50 mg
Synergism with other cytotoxic drugs. Caution when admin with drugs that inhibit phosphatase activity. Cyclosporin A may reduce the clearance of Toposar 50 mg.
Contraindications
Hypersensitivity, pregnancy, lactation.
Side Effects of Toposar 50 mg
Leukopenia, Nausea and Vomiting, Thrombocytopenia, Alopecia, Anorexia, Diarrhea, Leukopenia, Anemia, Pancytopenia, Stomatitis, Hepatic toxicity, Type 1 hypersensitivity, Orthostatic hypotension, Peripheral neuropathyMalaise,Shivering,Asthenia,Fever,Mucous membrane inflammation, Hyperuricemia, Local soft tissue toxicity has been reported following extravasation;
Pregnancy & Lactation
Pregnancy category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.Lactation: not known if excreted in breast milk, discontinue drug or do not nurse
Precautions & Warnings
Skin reactions may occur with accidental exposure; renal or hepatic disease. Periodic CBCs should be done before, during and after therapy. Increased risk of Toposar 50 mg-toxicity in patients with low serum albumin. Acrylic material has been shown to crack and leak when used with undiluted Toposar 50 mg inj.
Use In Special Populations
Renal impairment: CrCI: 15-50 ml/min- 75% of the recommended dose.
Drug Classes
Cytotoxic Chemotherapy
Mode Of Action
Toposar 50 mg is a derivative of podophyllotoxin that inhibits DNA synthesis resulting in the arrest of the cell cycle. At low doses, it inhibits cells from entering cell cycle and at high doses, cells entering mitosis are lysed.
Pregnancy
Pregnancy category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.Lactation: not known if excreted in breast milk, discontinue drug or do not nurse
Pediatric Uses
Renal impairment: CrCI: 15-50 ml/min- 75% of the recommended dose.
Disclaimer
The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.